Lupin has reported results for fourth quarter and year ended March 31, 2022.
The company has reported net loss of Rs 35.89 crore for the quarter under review as compared to net profit of Rs 316.36 crore for the same quarter in the previous year. However, total income of the company increased by 11.95% at Rs 2,871.54 crore for Q4FY22 as compared Rs 2,565.11 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported net loss after tax and before non-controlling Interest at Rs 511.73 crore for the quarter under review as compared to net profit of Rs 464.37 crore for the same quarter in the previous year. However, total income of the company increased by 1.75% at Rs 3,898.71 crore for Q4FY22 as compared Rs 3,831.74 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported net loss of Rs 188.70 crore as compared to net profit of Rs 1,258.62 crore for the previous year. However, total income of the company increased by 6.59% at Rs 11,922.09 crore for year under review as compared to Rs 11,185.02 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported net loss after tax and before non-controlling Interest at Rs 1509.36 crore as compared to net profit of Rs 1227.93 crore for the previous year. However, total income of the company increased by 8.16% at Rs 16,547.17 crore for year under review as compared to Rs 15,299.25 crore for year ended March 31, 2021.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.10 |
Dr. Reddys Lab | 1257.70 |
Cipla | 1558.95 |
Lupin | 2204.30 |
Zydus Lifesciences | 1000.25 |
View more.. |